A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade

Over the past decade, several immunotherapies have been approved for the treatment of melanoma. The most prominent of these are the immune checkpoint inhibitors, which are antibodies that block the inhibitory effects on the immune system by checkpoint receptors, such as CTLA-4, PD-1 and PD-L1. Precl...

Descripción completa

Detalles Bibliográficos
Autores principales: Milberg, Oleg, Gong, Chang, Jafarnejad, Mohammad, Bartelink, Imke H., Wang, Bing, Vicini, Paolo, Narwal, Rajesh, Roskos, Lorin, Popel, Aleksander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677731/
https://www.ncbi.nlm.nih.gov/pubmed/31375756
http://dx.doi.org/10.1038/s41598-019-47802-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677731/
https://www.ncbi.nlm.nih.gov/pubmed/31375756
http://dx.doi.org/10.1038/s41598-019-47802-4

Ejemplares similares